TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26849442
Drug: Direct observation
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct observation of treatment (DOT) provided by a family member
Study: 26849442
Drug: Direct observation
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct observation of treatment (DOT) provided by a non-family member (usual-practice)
Study: 20100767
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of both clinical seizures and subclinical seizure patterns (group A)
Study: 20100767
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (blinding of aEEG registration and treatment of clinical seizures only, group B)
Study: 20100767
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (group A)
Study: 2899840
Drug: Diltiazem (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (240 mg per day, n = 1234)
Study: 29473382
Drug: Solifenacin Succinate
Normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solifenacin Succinate (SS), 5 mg once a day for 12 weeks
Study: 29473382
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and Alternative Medicine (CAM), 930 mg twice daily for 12 weeks
Study: 25152207
Drug: Telbivudine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine plus PegIFN alpha‐2a (combination therapy)
Study: 25152207
Drug: Telbivudine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine monotherapy
Study: 25152207
Drug: PegIFN alpha‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFN alpha‐2a monotherapy
Study: 21211688
Drug: Absence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absence of beta-blockers
Study: 18241759
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (carotid artery stenting)
Study: 18241759
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (carotid endarterectomy)
Study: 12491829
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition plus enteral feeding (TPN + EF)
Study: 2651586
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment in semicomatose/stuporous patients
Study: 2651586
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment in semicomatose/stuporous patients
Study: 328033
Drug: Glafenin 200
Normalized name: Glafenine
DrugBank: Glafenine (DB08963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glafenin 200 mg three times daily
Study: 27825007
Drug: Standard 3-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 3-weekly chemotherapy
Study: 23505993
Drug: Transdiagnostic cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic cognitive-behavioral group therapy for anxiety
Study: 15449262
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation with polyethylene glycol (PEG)
Study: 15449262
Drug: Other bowel
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other bowel preparations
Study: 9143391
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interleukin-1 alpha (rhuIL-1 alpha) at doses of 0.1-10 micrograms/m2 for 4 days by subcutaneous injection before ICF chemotherapy
Study: 9143391
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interleukin-1 alpha (rhuIL-1 alpha) administered after ICE chemotherapy
Study: 9143391
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving standard chemotherapy without rhuIL-1 alpha
Study: 11823896
Drug: Chromium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chromium treatment
Study: 22031621
Drug: BMS‐690514, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐690514, 200 mg after a high‐fat meal (951 kcal, 52% fat)
Study: 22031621
Drug: BMS‐690514, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐690514, 200 mg after a light meal (336 kcal, 75% carbohydrate)
Study: 22031621
Drug: BMS‐690514, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐690514, 200 mg while fasting
Study: 20533105
Drug: Intensive sucralfate
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive sucralfate therapy plus conventional therapy
Study: 18466925
Drug: Buspirone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (15 mg/day)
Study: 18466925
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Estrogen 0.625 mg/d plus buspirone)
Study: 12142810
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.5 mg/kg, maximum dose of 20 mg) with IV meperidine (2 mg/kg, maximum dose of 100 mg)
Study: 12142810
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam (0.3 mg/kg, maximum dose of 10 mg) with IV meperidine (2 mg/kg, maximum dose of 100 mg)
Study: 9927110
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (weekly doses subcutaneously on Days -21, -14, -7, and day of surgery)
Study: 8667039
Drug: Cefodizime 1
Normalized name: cefodizime
DrugBank: Cefodizime (DB13470)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefodizime 1 g i.m. qD (Group A)
Study: 8667039
Drug: Cefodizime 1
Normalized name: cefodizime
DrugBank: Cefodizime (DB13470)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefodizime 1 g i.m. BID (Group B)
Study: 8667039
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g i.m. qD (Group C)
Study: 2201431
Drug: Doxorubicin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (70 mg/m2 intravenously)
Study: 2201431
Drug: Doxorubicin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (70 mg/m2 intravenously) and Vindesine (3 mg/m2 intravenously)
Study: 28002882
Drug: LC28-0126 (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC28-0126 (0.3, 1, 3, 10, 25, 50, 100, or 200 mg)
Study: 28002882
Drug: LC28-0126 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC28-0126 (0.3 to 200 mg)
Study: 26032952
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (1.5 mg NES/0.5 mg E2)
Study: 26032952
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose (3.0 mg NES/1.0 mg E2)
Study: 26032952
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (4.5 mg NES/1.5 mg E2)
Study: 23602417
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) with standard rehabilitation
Study: 11368131
Drug: Mifepristone 600
Normalized name: Mifepristone 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 600 mg followed by misoprostol 400 microg 6-8 hours later (Group 1)
Study: 11368131
Drug: Mifepristone 600
Normalized name: Mifepristone 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 600 mg followed by misoprostol 400 microg 48 hours later (Group 2)
Study: 1360776
Drug: 0.88 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.88 mg/kg oxatomide
Study: 1360776
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg oxatomide
Study: 6400576
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% prednisolone acetate
Study: 6400576
Drug: Steroid treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steroid treated group (intervention)
Study: 17896781
Drug: Local breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local breast irradiation and adjuvant therapy
Study: 16116154
Drug: Intensive alkylator-based
Normalized name: petroleum alkylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive alkylator-based induction chemotherapy with or without autologous bone marrow transplantation (ABMT) with or without 13 cis-retinoic acid.
Study: 12169044
Drug: Desloratadine 7.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 7.5mg daily with erythromycin 500mg every 8 hours for 10 days
Study: 12169044
Drug: Desloratadine 7.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 7.5mg daily with erythromycin
Study: 12169044
Drug: Desloratadine 7.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 7.5mg daily with placebo
Study: 10575337
Drug: Inhaled glutathione
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glutathione (600 mg)
Study: 27170445
Drug: BAT 1200
Normalized name: ODEVIXIBAT 1200MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAT 1200 μg via DPI-D
Study: 27170445
Drug: BAT 1200
Normalized name: ODEVIXIBAT 1200MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAT 1200 μg via DPI-E without a lactose-filled second strip
Study: 27170445
Drug: BAT 1200
Normalized name: ODEVIXIBAT 1200MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAT 1200 μg via DPI-E with a lactose-filled second strip
Study: 27170445
Drug: BAT/FF 1200/300
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAT/FF 1200/300 μg via DPI-E
Study: 27170445
Drug: FF 300
Normalized name: Gonal F RFF 300 UNT per 0.5 ML Pen Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF 300 μg via DPI-E with a lactose-filled second strip
Study: 27170445
Drug: BAT/FF 900/300
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAT/FF 900/300 μg via DPI-E
Study: 24526257
Drug: Prednisolone (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (2.0 mg/kg/d)
Study: 15556964
Drug: Epidural diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural diamorphine 3 mg (high-volume, low-concentration solution)
Study: 15556964
Drug: Epidural diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural diamorphine 3 mg (low-volume, high-concentration solution)
Study: 10566877
Drug: Phytosterol ester-enriched
Normalized name: phytosterol esters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterol ester-enriched margarine (40 g containing 8.6 g vegetable oil phytosterol)
Study: 10654588
Drug: Control margarine
Normalized name: MARGARINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control margarine (40 g)
Study: 6881974
Drug: Levamisole group
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole group (three-drug regimen: 5-FU, Adriamycin, and Levamisole)
Study: 6881974
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (two-drug regimen: 5-FU and Adriamycin)
Study: 31439467
Drug: Total Body
Normalized name: Total Body Massager Item
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Body Weight (TBW) dosing, 1.22 mL/kg
Study: 31439467
Drug: Lean Body
Normalized name: Cleanser Topical application Soap [NIVEA MEN ACTIVE CLEAN BODY WASH]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lean Body Weight (LBW) dosing, 1.66 mL/kg for women and 1.52 mL/kg for men
Study: 31439467
Drug: TBW dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBW dosing
Study: 31439467
Drug: LBW dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBW dosing
Study: 31439467
Drug: TBW and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBW and LBW dosing
Study: 28886351
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 or 30 mg)
Study: 30845095
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg)
Study: 30845095
Drug: Dexamethasone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (30 mg)
Study: 29023215
Drug: Monthly Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly Denosumab
Study: 29023215
Drug: Monthly Zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly Zoledronic Acid (ZA)
Study: 17890830
Drug: Quality improvement
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quality improvement (QI) programs involving medication or psychotherapy
Study: 15126132
Drug: Bendroflumethiazide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide (2.5 mg)
Study: 11669431
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg hyperbaric bupivacaine with added fentanyl 20 microg (group BF)
Study: 11669431
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg hyperbaric bupivacaine alone (group B)
Study: 7985742
Drug: SP/CQ (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP/CQ (treatment dose of sulfadoxine-pyrimethamine followed by weekly chloroquine prophylaxis)
Study: 7985742
Drug: SP/SP (two-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP/SP (two-dose sulfadoxine-pyrimethamine regimen)
Study: 30136704
Drug: Continuous Renal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Renal Replacement Therapy (CRRT) in addition to conventional therapy
Study: 10910028
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg daily)
Study: 18363314
Drug: Methylphenidate (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (mean daily dose of 36.7 +/- 11.2 mg over > or = 26 days)
Study: 12029450
Drug: Colloid infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid infusion
Study: 12029450
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no colloid infusion)
Study: 10999121
Drug: EPO therapy
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO therapy (40 U/kg biweekly for 6 weeks)
Study: 7261664
Drug: placebo creams
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo creams
Study: 28526920
Drug: semaglutide 1.0
Normalized name: SEMAGLUTIDE 1.0 mg in 0.5 mL SUBCUTANEOUS INJECTION, SOLUTION [WEGOVY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: semaglutide 1.0 mg once-weekly
Study: 23374910
Drug: Hotspot-targeted interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hotspot-targeted interventions including larviciding, focal screening and treatment, distribution of long-lasting insecticide-treated nets, and indoor residual spraying.
Study: 19320633
Drug: Baseline measures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline measures of perceived stress, drinking severity, psychiatric comorbidity, self-efficacy, craving, and positive treatment outcome expectancies
Study: 19116389
Drug: Beta carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta carotene (50 mg every other day)
Study: 15096081
Drug: Sertraline (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (titrated up to 50-150 mg/day)
Study: 15096081
Drug: Paroxetine (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (titrated up to 40-60 mg/day)
Study: 12106936
Drug: Spironolactone (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (12.5 to 50 mg/day)
Study: 27327441
Drug: Spironolactone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (50 mg)
Study: 9641366
Drug: Thyroxine 0.1
Normalized name: LEVOTHYROXINE 0.1MG/ML ORAL SOLN UD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxine 0.1 mg daily
Study: 7943696
Drug: Tubocurare (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tubocurare (0.125 mg.kg‐1 or 0.25 mg.kg‐1)
Study: 7943696
Drug: Suxamethonium (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium (1 mg.kg‐1)
Study: 3287770
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of pirenzepine (75 mg/day) and cimetidine (400 mg at bedtime)
Study: 3287770
Drug: Cimetidine monotherapy
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine monotherapy (1000 mg/day)
Study: 31888764
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (no cerebral oxygenation monitoring)
Study: 15163331
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no glucocorticoid treatment)
Study: 24699430
Drug: Standard memory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard memory therapy provided in the rehabilitation center
Study: 24113708
Drug: High-repetition, moderate-intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-repetition, moderate-intensity resistance training (n = 12) for 12 weeks, performed twice a week for 75 minutes per session.
Study: 19808135
Drug: Modafinil 300
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 300 mg/d
Study: 16807617
Drug: Eprosartan mesylate
Normalized name: Eprosartan Mesylate
DrugBank: Eprosartan (DB00876)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eprosartan mesylate 600 mg once daily
Study: 16807617
Drug: Eprosartan mesylate
Normalized name: Eprosartan Mesylate
DrugBank: Eprosartan (DB00876)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eprosartan mesylate 600 mg once daily plus HBPM
Study: 8418225
Drug: Octreotide at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide at a dosage of 0.1 mg subcutaneously twice per day for 3 days
Study: 8418225
Drug: Loperamide 4
Normalized name: loperamide 0.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide 4 mg orally initially and then 2 mg every 6 hours for 3 days
Study: 30516088
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard administration instructions)
Study: 28854956
Drug: Ultra-low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low dose RTX (1×500 mg or 1×200 mg)
Study: 28854956
Drug: Standard low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard low dose RTX (1×1000 mg)
Study: 20931328
Drug: Pentagastrin (cholecystokinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentagastrin (cholecystokinin type-2 receptor agonist)
Study: 20931328
Drug: Morphine (pre-conditioning)
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine (pre-conditioning)
Study: 20931328
Drug: Naloxone (μ-opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (μ-opioid receptor antagonist)
Study: 18814906
Drug: Short-acting human
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting human insulin (1 unit/kg)
Study: 20929566
Drug: Malaria intervention
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malaria intervention (intermittent screening and treatment of malaria)
Study: 16154017
Drug: Amlodipine-based combination
Normalized name: Amlodipine free base
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine-based combination drug regimen
Study: 16154017
Drug: Atenolol-based combination
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol-based combination drug regimen
Study: 14698800
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg buprenorphine per day
Study: 12039619
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg buprenorphine per day
Study: 12039619
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg buprenorphine per day
Study: 9569110
Drug: Intravesical BCG
Normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical BCG therapy (81 mg) in Group 1
Study: 9569110
Drug: Intravesical BCG
Normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical BCG therapy (54 mg) in Group 2
Study: 8306416
Drug: Mitomycin 20
Normalized name: mitomycin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin 20 mg/m2 only
Study: 8306416
Drug: Mitomycin 20
Normalized name: mitomycin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin 20 mg/m2 after pretreatment with WR-2721, 910 mg/m2
Study: 3189495
Drug: Blu Blocker
Normalized name: Blu-Kote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blu Blocker
Study: 30649344
Drug: Feeding sows
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feeding sows once daily at 1530 h
Study: 30649344
Drug: Control (Feeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Feeding sows once daily at 0730 h)
Study: 30649344
Drug: Feeding sows
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feeding sows daily at 1130 h
Study: 27545697
Drug: Colistin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin plus rifampicin (not detailed in dosage or duration)
Study: 19145637
Drug: Daming capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daming capsule (DMC) 2 g b.i.d. for 6 weeks
Study: 19145637
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg o.d. for 6 weeks
Study: 17325925
Drug: Iodixanol (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol (320 mg Iota/ml) used in MDCTA
Study: 15505151
Drug: Botulinum neurotoxin
Normalized name: Botulinum neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum neurotoxin (BoNT) type A injections into the submandibular salivary glands